Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Feb 07 04:00PM ET
8.21
Dollar change
-0.22
Percentage change
-2.61
%
IndexRUT P/E- EPS (ttm)-5.03 Insider Own9.82% Shs Outstand49.53M Perf Week1.73%
Market Cap406.77M Forward P/E- EPS next Y-0.61 Insider Trans-0.41% Shs Float44.68M Perf Month-1.79%
Income-238.81M PEG- EPS next Q-1.14 Inst Own85.91% Short Float13.62% Perf Quarter-7.96%
Sales84.33M P/S4.82 EPS this Y21.49% Inst Trans-8.14% Short Ratio4.56 Perf Half Y-31.81%
Book/sh6.09 P/B1.35 EPS next Y87.09% ROA-41.43% Short Interest6.09M Perf Year-37.09%
Cash/sh5.16 P/C1.59 EPS next 5Y28.23% ROE-71.87% 52W Range6.56 - 28.80 Perf YTD6.21%
Dividend Est.- P/FCF- EPS past 5Y- ROI-57.85% 52W High-71.49% Beta1.33
Dividend TTM- Quick Ratio3.05 Sales past 5Y111.76% Gross Margin34.76% 52W Low25.15% ATR (14)0.57
Dividend Ex-Date- Current Ratio3.05 EPS Y/Y TTM15.84% Oper. Margin-289.09% RSI (14)53.28 Volatility5.98% 7.47%
Employees344 Debt/Eq0.48 Sales Y/Y TTM-15.14% Profit Margin-283.19% Recom1.27 Target Price34.45
Option/ShortYes / Yes LT Debt/Eq0.37 EPS Q/Q16.66% Payout- Rel Volume0.40 Prev Close8.43
Sales Surprise2.39% EPS Surprise-4.25% Sales Q/Q-16.31% EarningsNov 06 AMC Avg Volume1.33M Price8.21
SMA206.07% SMA50-0.41% SMA200-27.42% Trades Volume539,100 Change-2.61%
Date Action Analyst Rating Change Price Target Change
Feb-07-25Resumed Raymond James Outperform $27
Nov-15-24Resumed Morgan Stanley Overweight $22
Oct-10-24Resumed Raymond James Outperform $18
Jun-07-24Initiated Goldman Buy $38
Mar-11-24Initiated H.C. Wainwright Buy $36
Mar-08-24Upgrade RBC Capital Mkts Sector Perform → Outperform $20 → $35
Mar-06-24Upgrade Leerink Partners Market Perform → Outperform $37
Feb-21-24Resumed Raymond James Outperform $45
Nov-01-23Initiated Stifel Buy $35
Jun-02-23Initiated Robert W. Baird Outperform $42
Jan-30-25 07:05AM
Jan-24-25 09:55AM
03:00AM
Jan-15-25 03:18PM
Jan-14-25 06:30AM
05:00AM Loading…
05:00AM
Jan-13-25 08:31AM
Jan-08-25 07:26AM
Dec-06-24 06:29PM
06:29PM
Nov-19-24 12:32PM
Nov-18-24 07:05AM
05:23AM
Nov-14-24 07:05AM
Nov-07-24 02:22AM
06:00PM Loading…
Nov-06-24 06:00PM
05:02PM
04:05PM
Nov-05-24 07:59AM
Nov-04-24 07:05AM
Oct-30-24 07:05AM
Oct-21-24 07:05AM
Oct-18-24 07:05AM
Oct-17-24 03:04PM
Sep-23-24 04:05PM
Sep-17-24 07:05AM
Sep-04-24 09:15AM
Sep-03-24 01:33PM
08:04AM
Aug-29-24 04:05PM
07:05AM Loading…
Aug-27-24 07:05AM
Aug-08-24 07:05AM
06:00AM
Aug-06-24 09:55AM
Aug-01-24 05:45PM
04:46PM
04:05PM
07:03AM
Jul-30-24 07:01PM
Jul-28-24 09:09AM
Jul-25-24 07:05AM
Jul-12-24 09:59AM
Jun-27-24 10:05AM
Jun-26-24 04:36PM
Jun-25-24 04:32AM
Jun-24-24 12:56PM
07:05AM
Jun-21-24 04:28PM
06:40AM
Jun-18-24 07:05AM
07:02AM
Jun-12-24 08:00AM
07:05AM
Jun-05-24 07:05AM
May-15-24 11:38AM
May-10-24 02:30PM
07:05AM
May-09-24 03:53PM
11:11AM
07:11AM
03:46AM
May-08-24 09:56PM
05:40PM
04:44PM
04:05PM
May-01-24 07:05AM
Apr-24-24 07:05AM
Mar-28-24 01:09PM
07:05AM
Mar-27-24 04:05PM
Mar-18-24 07:00PM
Mar-13-24 08:00AM
Mar-11-24 07:05AM
Mar-08-24 01:29AM
Mar-06-24 11:20PM
04:10PM
11:33AM
03:01AM
Mar-05-24 07:05AM
Feb-29-24 04:57PM
Feb-28-24 11:05AM
09:36AM
Feb-27-24 05:35PM
04:41PM
04:32PM
04:05PM
Feb-21-24 07:05AM
Feb-17-24 12:07AM
Feb-08-24 09:36AM
04:50AM
Feb-07-24 11:40AM
07:05AM
Jan-31-24 07:05AM
Jan-18-24 09:01PM
Jan-16-24 02:47PM
Jan-10-24 07:05AM
Jan-09-24 06:20PM
Jan-08-24 07:05AM
Dec-22-23 09:01AM
Nov-29-23 07:05AM
REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
VITTAL VASISTAOfficerDec 30 '24Proposed Sale7.4120,041148,504Dec 30 04:09 PM
KARABELAS ARGERIS NDirectorOct 01 '24Option Exercise3.7610,00037,60021,286Oct 02 04:31 PM
KARABELAS ARGERIS NDirectorOct 01 '24Sale10.1110,000101,05211,286Oct 02 04:31 PM
KARABELAS ARGERIS NDirectorSep 03 '24Option Exercise3.7610,00037,60021,286Sep 04 08:20 PM
KARABELAS ARGERIS NDirectorSep 03 '24Sale11.5610,000115,58811,286Sep 04 08:20 PM
Mills Kenneth T.DirectorAug 08 '24Option Exercise0.8536,31630,869444,351Aug 12 04:58 PM
KARABELAS ARGERIS NDirectorAug 01 '24Option Exercise3.8510,10038,87421,386Aug 05 06:39 PM
KARABELAS ARGERIS NDirectorAug 01 '24Sale13.5110,100136,45411,286Aug 05 06:39 PM
Simpson CurranChief Executive OfficerAug 01 '24Sale15.001001,500170,037Aug 05 06:39 PM
ARGERIS N KARABELASDirectorAug 01 '24Proposed Sale14.2531,000441,750Aug 01 04:34 PM
KARABELAS ARGERIS NDirectorJul 29 '24Option Exercise12.7411,000140,14022,286Jul 30 05:01 PM
KARABELAS ARGERIS NDirectorJul 29 '24Sale15.0411,000165,49511,286Jul 30 05:01 PM
Simpson CurranChief Executive OfficerJul 29 '24Sale15.049,648145,106170,137Jul 30 05:01 PM
CURRAN M SIMPSONDirectorJul 29 '24Proposed Sale14.3325,106359,769Jul 29 04:13 PM
Mills Kenneth T.DirectorJul 25 '24Option Exercise3.7615,36957,787423,404Jul 26 05:00 PM
Mills Kenneth T.DirectorJul 24 '24Option Exercise3.7612,22145,951420,256Jul 26 05:00 PM
Mills Kenneth T.DirectorJul 25 '24Sale13.9615,369214,501408,035Jul 26 05:00 PM
Mills Kenneth T.DirectorJul 24 '24Sale13.7812,221168,433408,035Jul 26 05:00 PM
Mills Kenneth T.DirectorJul 17 '24Option Exercise3.762,2108,310410,245Jul 18 05:05 PM
Mills Kenneth T.DirectorJul 16 '24Option Exercise3.76200752408,235Jul 18 05:05 PM
Mills Kenneth T.DirectorJul 17 '24Sale13.772,21030,440408,035Jul 18 05:05 PM
Mills Kenneth T.DirectorJul 16 '24Sale13.762002,752408,035Jul 18 05:05 PM
KARABELAS ARGERIS NDirectorJul 01 '24Option Exercise3.7610,00037,60021,286Jul 03 07:55 AM
KARABELAS ARGERIS NDirectorJul 01 '24Sale11.2710,000112,69111,286Jul 03 07:55 AM
Mills Kenneth T.President and CEOMay 14 '24Option Exercise3.7615,00056,400423,035May 16 05:06 PM
Mills Kenneth T.President and CEOMay 14 '24Sale15.8115,000237,222408,035May 16 05:06 PM
Mills Kenneth T.President and CEOApr 15 '24Option Exercise3.7615,00056,400423,035Apr 17 05:05 PM
Mills Kenneth T.President and CEOApr 15 '24Sale18.1915,000272,871408,035Apr 17 05:05 PM
Vasista VittalChief Financial OfficerMar 19 '24Option Exercise3.7620,04175,354246,534Mar 21 05:20 PM
Mills Kenneth T.President and CEOMar 14 '24Option Exercise3.7615,00056,400423,035Mar 18 05:03 PM
Mills Kenneth T.President and CEOMar 14 '24Sale21.8615,000327,942408,035Mar 18 05:03 PM
PAKOLA STEVEChief Medical OfficerMar 05 '24Option Exercise22.2512,878286,536120,070Mar 07 06:05 PM
PAKOLA STEVEChief Medical OfficerMar 05 '24Sale28.3612,878365,220107,192Mar 07 06:05 PM
Mills Kenneth T.President and CEOFeb 14 '24Option Exercise3.7615,00056,400423,035Feb 16 06:28 PM
Mills Kenneth T.President and CEOFeb 14 '24Sale16.7615,000251,349408,035Feb 16 06:28 PM